Lipella Pharmaceuticals Inc. Common Stock (LIPO) - Net Assets
Based on the latest financial reports, Lipella Pharmaceuticals Inc. Common Stock (LIPO) has net assets worth $1.49 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.35 Million) and total liabilities ($862.22K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Lipella Pharmaceuticals Inc. Common Stoc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.49 Million |
| % of Total Assets | 63.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | 314.29% |
| 10-Year Change | N/A |
| Growth Volatility | 127.09 |
Lipella Pharmaceuticals Inc. Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Lipella Pharmaceuticals Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see LIPO stock market capitalisation.
Annual Net Assets for Lipella Pharmaceuticals Inc. Common Stock (2019–2024)
The table below shows the annual net assets of Lipella Pharmaceuticals Inc. Common Stock from 2019 to 2024. Also explore LIPO net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.92 Million | -38.96% |
| 2023-12-31 | $3.14 Million | -32.75% |
| 2022-12-31 | $4.68 Million | +228.45% |
| 2021-12-31 | $1.42 Million | +207.25% |
| 2020-12-31 | $463.32K | +491.51% |
| 2019-12-31 | $-118.34K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lipella Pharmaceuticals Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1416004900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $121.00 | 0.01% |
| Other Components | $17.26 Million | 899.19% |
| Total Equity | $1.92 Million | 100.00% |
Lipella Pharmaceuticals Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Lipella Pharmaceuticals Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Soosung Innovation Co. Ltd.
KQ:084180
|
$927.35 |
|
Effector Therapeutics Inc
NASDAQ:EFTR
|
$940.00 |
|
Bank Cimb Niaga Tbk
JK:BNGA
|
$960.54 |
|
Carzo Holdings Bhd
KLSE:03048
|
$969.60 |
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
$902.00 |
|
DIH Holdings US, Inc. Class A Common Stock
NASDAQ:DHAI
|
$837.06 |
|
IRPC Public Company Limited
F:TPIG
|
$811.55 |
|
Data Storage Corporation
NASDAQ:DTSTW
|
$768.53 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lipella Pharmaceuticals Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,144,448 to 1,919,453, a change of -1,224,995 (-39.0%).
- Net loss of 5,016,264 reduced equity.
- New share issuances of 2,841,872 increased equity.
- Other factors increased equity by 949,397.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.02 Million | -261.34% |
| Share Issuances | $2.84 Million | +148.06% |
| Other Changes | $949.40K | +49.46% |
| Total Change | $- | -38.96% |
Book Value vs Market Value Analysis
This analysis compares Lipella Pharmaceuticals Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.46 | $0.00 | x |
| 2020-12-31 | $1.74 | $0.00 | x |
| 2021-12-31 | $3.34 | $0.00 | x |
| 2022-12-31 | $9.21 | $0.00 | x |
| 2023-12-31 | $4.19 | $0.00 | x |
| 2024-12-31 | $1.83 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lipella Pharmaceuticals Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -261.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -935.25%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.39x
- Recent ROE (-261.34%) is below the historical average (-101.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -8.90% | 5.84x | 0.00x | $-50.01K |
| 2020 | -13.31% | -6.41% | 1.01x | 2.06x | $-107.99K |
| 2021 | -131.04% | -719.30% | 0.13x | 1.41x | $-2.01 Million |
| 2022 | -55.56% | -1410.59% | 0.03x | 1.27x | $-3.07 Million |
| 2023 | -146.89% | -1027.31% | 0.13x | 1.14x | $-4.93 Million |
| 2024 | -261.34% | -935.25% | 0.20x | 1.39x | $-5.21 Million |
Industry Comparison
This section compares Lipella Pharmaceuticals Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lipella Pharmaceuticals Inc. Common Stock (LIPO) | $1.49 Million | 0.00% | 0.58x | $924.00 |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Lipella Pharmaceuticals Inc. Common Stock
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen plan… Read more